vs
Side-by-side financial comparison of Journey Medical Corp (DERM) and FGI Industries Ltd. (FGI). Click either name above to swap in a different company.
FGI Industries Ltd. is the larger business by last-quarter revenue ($30.5M vs $16.1M, roughly 1.9× Journey Medical Corp). Journey Medical Corp runs the higher net margin — -7.8% vs -8.6%, a 0.9% gap on every dollar of revenue. On growth, Journey Medical Corp posted the faster year-over-year revenue change (27.3% vs -14.4%). Over the past eight quarters, Journey Medical Corp's revenue compounded faster (11.0% CAGR vs -0.5%).
Journey Medical Corp is a commercial-stage biopharmaceutical company specializing in dermatology treatments. It develops, manufactures and markets prescription and over-the-counter products addressing acne, atopic dermatitis, fungal skin infections and other dermal conditions, primarily serving healthcare providers and patients across the United States.
FGI Industries Ltd is a global designer, manufacturer and distributor of kitchen and bath products, home organization solutions, and home improvement goods. It serves major retail chains, home specialty stores and e-commerce platforms across North America, Europe and the Asia-Pacific region.
DERM vs FGI — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $16.1M | $30.5M |
| Net Profit | $-1.2M | $-2.6M |
| Gross Margin | — | 26.7% |
| Operating Margin | -2.8% | -2.2% |
| Net Margin | -7.8% | -8.6% |
| Revenue YoY | 27.3% | -14.4% |
| Net Profit YoY | -182.0% | -553.1% |
| EPS (diluted) | $-0.04 | $-1.63 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $16.1M | $30.5M | ||
| Q3 25 | $17.0M | $35.8M | ||
| Q2 25 | $15.0M | $31.0M | ||
| Q1 25 | $13.1M | $33.2M | ||
| Q4 24 | $12.6M | $35.6M | ||
| Q3 24 | $14.6M | $36.1M | ||
| Q2 24 | $14.9M | $29.4M | ||
| Q1 24 | $13.0M | $30.8M |
| Q4 25 | $-1.2M | $-2.6M | ||
| Q3 25 | $-2.3M | $-1.7M | ||
| Q2 25 | $-3.8M | $-1.2M | ||
| Q1 25 | $-4.1M | $-629.1K | ||
| Q4 24 | $1.5M | $-402.3K | ||
| Q3 24 | $-2.4M | $-550.1K | ||
| Q2 24 | $-3.4M | $163.6K | ||
| Q1 24 | $-10.4M | $-412.2K |
| Q4 25 | — | 26.7% | ||
| Q3 25 | — | 26.5% | ||
| Q2 25 | — | 28.1% | ||
| Q1 25 | — | 26.8% | ||
| Q4 24 | 82.3% | 24.6% | ||
| Q3 24 | 63.9% | 25.8% | ||
| Q2 24 | 56.0% | 30.5% | ||
| Q1 24 | 47.7% | 27.4% |
| Q4 25 | -2.8% | -2.2% | ||
| Q3 25 | -9.0% | 1.0% | ||
| Q2 25 | -19.2% | -2.7% | ||
| Q1 25 | -25.3% | -3.9% | ||
| Q4 24 | 17.7% | -3.5% | ||
| Q3 24 | -19.8% | -0.2% | ||
| Q2 24 | -19.7% | -1.5% | ||
| Q1 24 | -77.4% | -1.0% |
| Q4 25 | -7.8% | -8.6% | ||
| Q3 25 | -13.6% | -4.6% | ||
| Q2 25 | -25.3% | -4.0% | ||
| Q1 25 | -31.0% | -1.9% | ||
| Q4 24 | 12.1% | -1.1% | ||
| Q3 24 | -16.3% | -1.5% | ||
| Q2 24 | -22.6% | 0.6% | ||
| Q1 24 | -80.1% | -1.3% |
| Q4 25 | $-0.04 | $-1.63 | ||
| Q3 25 | $-0.09 | $-0.86 | ||
| Q2 25 | $-0.16 | $-0.64 | ||
| Q1 25 | $-0.18 | $-0.07 | ||
| Q4 24 | $0.10 | $-0.38 | ||
| Q3 24 | $-0.12 | $-0.29 | ||
| Q2 24 | $-0.17 | $0.08 | ||
| Q1 24 | $-0.53 | $-0.04 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $24.1M | $1.9M |
| Total DebtLower is stronger | $25.3M | — |
| Stockholders' EquityBook value | $31.9M | $17.3M |
| Total Assets | $94.6M | $69.5M |
| Debt / EquityLower = less leverage | 0.79× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $24.1M | $1.9M | ||
| Q3 25 | $24.9M | $1.9M | ||
| Q2 25 | $20.3M | $2.5M | ||
| Q1 25 | $21.1M | $1.2M | ||
| Q4 24 | $20.3M | $4.6M | ||
| Q3 24 | $22.5M | $3.0M | ||
| Q2 24 | $23.9M | $1.3M | ||
| Q1 24 | $24.1M | $3.3M |
| Q4 25 | $25.3M | — | ||
| Q3 25 | $25.2M | — | ||
| Q2 25 | $25.1M | — | ||
| Q1 25 | $25.0M | — | ||
| Q4 24 | $24.9M | — | ||
| Q3 24 | $19.8M | — | ||
| Q2 24 | $19.7M | — | ||
| Q1 24 | $14.7M | — |
| Q4 25 | $31.9M | $17.3M | ||
| Q3 25 | $25.9M | $19.7M | ||
| Q2 25 | $19.2M | $21.3M | ||
| Q1 25 | $21.5M | $21.8M | ||
| Q4 24 | $20.1M | $22.3M | ||
| Q3 24 | $10.9M | $23.5M | ||
| Q2 24 | $11.3M | $23.8M | ||
| Q1 24 | $13.0M | $23.9M |
| Q4 25 | $94.6M | $69.5M | ||
| Q3 25 | $85.2M | $73.0M | ||
| Q2 25 | $81.2M | $71.7M | ||
| Q1 25 | $85.0M | $68.5M | ||
| Q4 24 | $80.2M | $75.5M | ||
| Q3 24 | $64.0M | $74.7M | ||
| Q2 24 | $65.2M | $69.9M | ||
| Q1 24 | $66.6M | $68.6M |
| Q4 25 | 0.79× | — | ||
| Q3 25 | 0.97× | — | ||
| Q2 25 | 1.30× | — | ||
| Q1 25 | 1.16× | — | ||
| Q4 24 | 1.24× | — | ||
| Q3 24 | 1.81× | — | ||
| Q2 24 | 1.75× | — | ||
| Q1 24 | 1.13× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-6.3M | $2.3M |
| Free Cash FlowOCF − Capex | — | $2.3M |
| FCF MarginFCF / Revenue | — | 7.5% |
| Capex IntensityCapex / Revenue | — | 0.2% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-212.5K |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-6.3M | $2.3M | ||
| Q3 25 | $-2.4M | $-1.9M | ||
| Q2 25 | $-942.0K | $7.6M | ||
| Q1 25 | $-2.8M | $-7.4M | ||
| Q4 24 | $2.2M | $617.4K | ||
| Q3 24 | $-1.2M | $-915.0K | ||
| Q2 24 | $-5.2M | $862.1K | ||
| Q1 24 | $-5.0M | $-8.0M |
| Q4 25 | — | $2.3M | ||
| Q3 25 | — | $-2.1M | ||
| Q2 25 | — | $7.4M | ||
| Q1 25 | — | $-7.7M | ||
| Q4 24 | — | $-214.1K | ||
| Q3 24 | — | $-1.1M | ||
| Q2 24 | — | $281.5K | ||
| Q1 24 | — | $-8.6M |
| Q4 25 | — | 7.5% | ||
| Q3 25 | — | -5.9% | ||
| Q2 25 | — | 23.8% | ||
| Q1 25 | — | -23.3% | ||
| Q4 24 | — | -0.6% | ||
| Q3 24 | — | -3.0% | ||
| Q2 24 | — | 1.0% | ||
| Q1 24 | — | -28.0% |
| Q4 25 | — | 0.2% | ||
| Q3 25 | — | 0.7% | ||
| Q2 25 | — | 0.7% | ||
| Q1 25 | — | 1.1% | ||
| Q4 24 | — | 2.3% | ||
| Q3 24 | — | 0.5% | ||
| Q2 24 | — | 2.0% | ||
| Q1 24 | — | 2.0% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 1.46× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 5.27× | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
DERM
| Qbrexza | $5.5M | 35% |
| Emrosi | $5.0M | 31% |
| Accutane | $3.1M | 19% |
| Other | $2.5M | 15% |
FGI
| Sanitaryware | $19.1M | 63% |
| Shower System | $5.8M | 19% |
| Kitchen And Bath Other | $3.3M | 11% |
| Bath Furniture Products | $2.3M | 7% |
